Mehdi Gasmi officiates as COO/CSO at SparingVision a clinical stage ocular genomics medicine company since 2021. He is a seasoned executive with close to 30 years of experience across the gene therapy drug development field, including in ophthalmology indications.

Dr Gasmi’s deep experience in the design and translational development of gene therapy drug candidates has been garnered through a multitude of posts, as a Board member and prior to that, as President and Chief Scientific Officer at Adverum Biotechnologies Inc. in California, USA. During his time as CSO of Adverum, Mehdi Gasmi led the company’s R&D and translational operations for AAV-based gene therapy products, specifically ixoberogen soroparvovec, a treatment for ocular VEGF-driven diseases.

Prior to Adverum, he held numerous roles at gene therapy companies both in the US and in Europe, including Genethon, Ceregene, Cell Genesys and Chiron. In addition to his corporate experience, he worked on the development of HIV-based vectors for gene delivery at academic institutions including City of Hope and the University of California, San Diego.

Mehdi Gasmi received a MSc and PhD in Biochemistry from the Claude Bernard University, Lyon.